Richard Markiewicz, MD
Interventional Cardiology · North Platte, NENPI 1780725580
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Inari Medical, Inc. accounts for 86.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $17,949 and has fallen 99.9% since, to $14 in 2025.
Across 127 payments — averaging $257.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$28K
- Medtronic$2K
- Boston Scientific$1K
- Terumo Medical Corporation$522
- Philips North America LLC$238
- Siemens Medical Solutions USA, Inc.$200
- plus $722 from 14 others
What the payments were for
- Consulting fees$16,00049%
- Speaking & faculty fees$9,25028%
- Travel & lodging$3,75712%
- Food & beverage$3,64311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 25 | $28,355 |
| Medtronic(2 entities) | 25 | $1,532 |
| Boston Scientific | 29 | $1,080 |
| Terumo Medical Corporation | 12 | $522 |
| Philips North America LLC | 4 | $238 |
| Siemens Medical Solutions USA, Inc. | 3 | $200 |
| Abiomed | 1 | $144 |
| Cardiovascular Systems Inc. | 5 | $105 |
| Pfizer | 6 | $88 |
| Abbott | 1 | $67 |
| Saranas, Inc. | 2 | $62 |
| Edwards Lifesciences | 2 | $55 |
| Getinge USA Sales, LLC | 2 | $41 |
| Novartis | 2 | $30 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Shockwave Medical, Inc | 2 | $27 |
| Amgen | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $18 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$37,208
- FLOWTRIEVER CATHETER, S$17,778
- COREVALVE EVOLUT R$799
- GENERAL VASCULAR ACCESS$716
- FlowTriever$624
- ClotTriever$624
- GLIDESHEATH SLENDER$221
- Impella$144
- Navicross$110
- METACROSS OTW$110
- R2P MISAGO$110
How this compares
$32,650 in reported general payments places this provider in the 80th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $29,865 |
| Repatha SureclickEvolocumab | 30 | $20,537 |
| XareltoRivaroxaban | 16 | $12,954 |
| ClopidogrelClopidogrel Bisulfate | 377 | $3,157 |
| Ranolazine ErRanolazine | 50 | $2,096 |
| Atorvastatin Calcium | 194 | $1,359 |
| Carvedilol | 150 | $1,268 |
| Pantoprazole Sodium | 89 | $1,038 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 74 | $835 |
| Metoprolol Succinate | 80 | $808 |
| Bumetanide | 15 | $463 |
| Rosuvastatin Calcium | 42 | $442 |
| Metoprolol Tartrate | 67 | $388 |
| Losartan Potassium | 54 | $321 |
| Amlodipine Besylate | 64 | $299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $29,86533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 interventional cardiology providers in Nebraska.
Other interventional cardiology in North Platte
- Bassent BotrosNorth Platte$16K
- Brock CookmanLincoln$782K
- Himanshu AgarwalOmaha$541K
- Matthew JohnsonLincoln$162K
- Poonam VelagapudiOmaha$142K
- Steven MartinLincoln$55K
- Andrew GoldsweigOmaha$49K
- Jai ParekhOmaha$44K
- James HallKearney$36K
- Scott CarolloOmaha$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.